Promensil Sponsors America’s First 'Baby Boomer' Pageant

Ms. Golden America Pageant contestants receive a 30-day supply of Promensil

Naples, Fla. October 16, 2005 -- Promensil, a natural supplement that relieves the symptoms of menopause, has announced it is a product sponsor for the Ms. Golden America Pageant, which will be held on October 29, 2005, at the Harborside Event Center in Fort Myers, Fla.

Ms. Golden America is a pageant focusing on the beauty and accomplishments of women age 50 and older. While 750 women from around the country applied to compete in the inaugural pageant, only 15 will vie for the title of Ms. Golden America. The five categories of competition are: tennis wear, consumer appeal, written essay, traditional evening gowns and on-stage questions.

Ms. Golden America will be broadcast as a one-hour special on the SkyAngel cable network on December 17, 2005.

Promensil is a natural supplement that has been clinically proven to relieve the symptoms of menopause, including hot flashes and night sweats, as well as maintain bone and cardiovascular health; Promensil Post Menopause is designed to help post midlife women maintain bone and cholesterol health after menopause. Both are products of Novogen, Ltd, world leader in isoflavone research, and can be purchased over the counter at pharmacies, health food/nutrition/vitamin and retail stores everywhere. For more information, visit www.promensil.com.

Information about the Ms. Golden America Pageant may be obtained by calling Kathleen LeSage at 1-800 545-9407 or on their website, www.msgoldenamerica.com.

Novogen, Ltd., is the world leader in research and development of isoflavones for human health. Isoflavones derived from the red clover plant, marketed under the brand name Promensil, have been clinically proven safe and effective in treating the symptoms of menopause and improving cardiovascular and bone health.

Phenoxodiol, the Company's leading anti-cancer compound, has received Fast Track designation for recurrent ovarian cancer as well as for hormone refractory prostate cancer from the Food and Drug Administration in the U.S. The rights to commercialize this drug are licensed to the Company's majority owned subsidiary, Marshall Edwards, Inc., (Nasdaq: MSHL - News; LSE-AIM: MSHL). More information can be found at http://www.novogen.com and http://www.marshalledwardsinc.com.

###